Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

BACKGROUND: Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk, and rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lugner, Moa, Sattar, Naveed, Miftaraj, Mervete, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983265/
https://www.ncbi.nlm.nih.gov/pubmed/33752680
http://dx.doi.org/10.1186/s12933-021-01258-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983265/
https://www.ncbi.nlm.nih.gov/pubmed/33752680
http://dx.doi.org/10.1186/s12933-021-01258-x

Ejemplares similares